Anlon Healthcare 1:5 Stock Split, 1:1 Bonus Issue Approved; Shares Rise 4.45%

Mumbai, March 6: Anlon Healthcare Limited shares closed higher by 4.45% at ₹116.00 on the National Stock Exchange on Friday after the company approved a sub-division of equity shares and a subsequent bonus issue following a board meeting.

The board approved a sub-division of equity shares from a face value of ₹10 each into five equity shares with a face value of ₹2 each fully paid up. The corporate action will apply to shareholders whose names appear in the company’s records on a record date that will be announced later, according to an exchange filing under SEBI Listing Obligations and Disclosure Requirements Regulations.

According to the disclosure, the share split is intended to improve liquidity in the company’s equity shares and facilitate broader participation from retail investors. The company said the implementation of the sub-division is subject to shareholder approval and completion of statutory requirements.

Alongside the split, the board also approved a bonus issue in the ratio of 1:1. Eligible shareholders will receive one bonus equity share of face value ₹2 for every one equity share of ₹2 held after the split. The bonus shares will be issued from free reserves available as of December 31, 2025.

Share Price Reaction on March 6, 2026

Anlon Healthcare shares ended the trading session at ₹116.00 on March 6, 2026, representing a gain of 4.45% compared with the previous close of ₹111.06, according to exchange data.

During the trading session the stock opened at ₹109.86 and moved to an intraday high of ₹118.72 before settling near the upper range of the day’s movement. The announcement of multiple corporate actions, including the stock split and bonus issue, coincided with increased investor activity in the counter.

Market participants typically view share splits and bonus issues as liquidity enhancing measures. By increasing the number of shares in circulation and lowering the effective trading price per share, such actions may improve accessibility for a broader base of investors.

Capital Structure Changes And Implementation Timeline

Following the sub-division, the authorised share capital structure will reflect equity shares with a face value of ₹2 each. The existing authorised capital of ₹55,00,00,000 divided into 5,50,00,000 equity shares of ₹10 each will be reclassified into 27,50,00,000 equity shares of ₹2 each.

The board also approved an increase in authorised share capital to ₹1,10,00,00,000. This will be effected through the creation of additional equity shares of ₹2 each, subject to shareholder approval and other applicable statutory clearances.

As per the company’s filing, the bonus issue will involve the issuance of approximately 26,57,57,500 equity shares of ₹2 each fully paid up. After the bonus allotment, the paid-up equity share capital will double in line with the 1:1 bonus ratio.

The company indicated that the bonus shares are expected to be credited or dispatched within two months from the date of board approval, meaning on or before May 6, 2026, subject to regulatory and shareholder approvals.

Company Background

Anlon Healthcare Limited operates in the healthcare and medical equipment distribution segment. The company supplies a range of healthcare products and medical devices across hospitals, diagnostic centres and healthcare institutions.

The firm has expanded its distribution network across multiple regions in India, focusing on the supply of specialised healthcare equipment and consumables. Its operations include sourcing, distribution and logistics management within the healthcare supply chain.

As of March 6, 2026, the company had a market capitalisation of approximately ₹616.56 crore, according to exchange data. The stock’s price to earnings ratio stood at 15.73, with a 52 week trading range between ₹90.78 and ₹172.75.

Conclusion

The board’s approval of a stock split followed by a 1:1 bonus issue marks a significant capital restructuring initiative for Anlon Healthcare Limited. According to the company’s regulatory filing, the actions are intended to improve liquidity in the equity shares and widen shareholder participation.

Final implementation will depend on shareholder approval and completion of statutory procedures, with the record dates for both corporate actions to be announced separately through stock exchange disclosures.

Source:

• https://nsearchives.nseindia.com/corporate/ANLON2013_06032026144607_AHLOutcomeofBM06032026Signed.pdf
• https://www.nseindia.com/get-quote/equity/AHCL/Anlon-Healthcare-Limited